Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution

A technology for injections and solutions, applied in drug combinations, cardiovascular system diseases, antiviral agents, etc., can solve problems such as inconvenient administration, virus recombination, mutation, etc., to avoid strong species specificity and reduce drug residues Harm, effect of low effective dose

Inactive Publication Date: 2013-10-30
QINGDAO AGRI UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, the patent application No. 95111433.6 of the invention patent "human leukocyte interferon buccal tablets and its preparation method" directly uses human leukocyte interferon plus excipients to make tablets, but the instructions show that the preparation has hormone properties and is suitable for human use. Potential risks; as another example, the invention patent with application number 200310110892.2 "Compound Interferon Inducing Agent Buccal Tablet" and the invention patent with application number 90101032.4 "Manufacturing method of inducing interferon in human body" use Newcastle disease Live attenuated vaccines are used as interferon-inducing agents, and the introduction of exogenous viruses will also bring potential risks of virus recombination and mutation; the invention patent with application number 200810154198.3 "a polymyocyte dripping pill for pets and its preparation method", and the invention patent "polymyocyte complex immune adjuvant and vaccine containing the adjuvant" with application number ZL93105862. It is inconvenient to administer medicine in drinking water for intensive aquaculture, and it is even more inconvenient to administer medicine by dipping in aquaculture

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution
  • Preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution
  • Preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment 1: 30 weaned piglets with similar birth age and body weight were selected as experimental animals to test the prevention and treatment effect of polyinosinic acid injection on classical swine fever virus infection. The experimental animals were randomly divided into three experimental groups, 10 animals in each group. Grouping and test methods are as follows: Group I: blank control group (normal saline group); Group II: astragalus polysaccharide drug control group (astragalus polysaccharide injection, 20 mg per kg body weight); Group III: polyinosinic acid drug control group (Polyinosinic acid injection, 0.05mg per kilogram of body weight). The weaned piglets were grouped and raised in isolation according to the above experiments, and the feeding conditions were kept the same. After feeding for 1 week, each group received basic immunization with attenuated classical swine fever vaccine. After 21 days of immunization, each group was treated with drugs accord...

Embodiment 2

[0020]Example 2: 120 AA broilers were selected as experimental animals to test the protective effect of polyinosinic acid solution on Newcastle disease virus infection. The chicks used in the experiment were hatched and brooded until they were 7 days old, and they were given basic immunization with eye drops and nasal drops of attenuated Newcastle disease vaccine. Then the test chicks were randomly divided into 3 test groups, 40 in each group. Group I: blank control group (normal saline group); Group II: astragalus polysaccharide drug control group (astragalus polysaccharide oral liquid, 40 mg per kilogram of body weight); Group III: polyinosinic acid solution test group (polyinosinic acid Solution, 0.05mg per kilogram of body weight); the above chicks were kept in isolation cages, and the feeding conditions were kept consistent. 10d after immunization, each group will be treated with drugs according to the grouping plan, and will be challenged after 12h (challenge 10 times L...

Embodiment 3

[0022] Embodiment 3: 120 test rainbow trout juveniles were randomly and equally divided into 3 test groups for testing, with 40 fish in each group. Group I: blank control group (normal saline group); Group II: astragalus polysaccharide drug control group (astragalus polysaccharide oral liquid, 30 mg per kilogram of body weight); Group III: polyinosin drug control group (polyinosinic acid solution, 0.05mg per kilogram of body weight). The drugs used in each group were used in the form of medicated baths. The rainbow trout juveniles were isolated and reared in aquariums according to the above experiments, and the feeding conditions were kept the same. After one week of feeding, each group was given medicine according to the plan. During the medicinal bath, most of the water was released from the aquarium, and the medicine was added to maintain oxygenation. The medicinal bath was 30 minutes, and then water was added to a constant value. After 12 hours, add 100 times LD to each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution, relating to a pharmaceutical composition for treating and curing breeding animal viral infection by improving the inducement level of endogenous interferon. The invention uses endogenous interferon induction technology, avoids the defects of strong specificity of self species of interferon preparation, is convenient to apply in production and practice by drug administration in various modes and has the characteristics of low onset dose and the like, and degradation products can directly enter an animal body metabolic pool to continue metabolizing. In addition, the invention has an important meaning for effectively controlling raised animal viral infection and lowering drug residue harm.

Description

Technical field: [0001] The invention relates to a drug combination for preventing and treating viral infection of farmed animals by inducing an increase in the level of endogenous interferon; in particular, it relates to the preparation of the drug for the combination and a preparation method for various applications. Background technique: [0002] Viral infection is an important factor that causes the death of farmed animals and affects the economic benefits of animal breeding. With the standardization of national veterinary drug quality standards, a large number of antiviral drugs with original local standards have been cancelled. Demand contradictions are becoming increasingly prominent. [0003] In 1967, Field et al. of Merck Pharmaceutical Company in the United States discovered that enzymatically synthesized double-stranded nucleic acid (double strained RNA, dsRNA) has the ability to induce interferon, wherein the induction of polyinosinic-polycytidylic acid (PIC) It...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/787A61P31/12A61P9/08A61P9/10
Inventor 刘宗柱
Owner QINGDAO AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com